LACTOLOGY FOUNDATION

Sulfaguanidine (ATC A07AB03) is an oral intestinal sulfonamide antibacterial used mainly for gastrointestinal infections such as bacillary dysentery, acting primarily within the gut lumen. Its poor systemic absorption means maternal plasma levels are low and transfer into breast milk is expected to be small, but as a sulfonamide it carries the usual theoretical risks in vulnerable neonates and therefore requires cautious use during breastfeeding.drugbank+3

Pharmacological class and indications

Sulfaguanidine is a sulfonamide antibiotic classified in ATC subgroup A07AB “Intestinal sulfonamides,” indicated for acute or chronic diarrhea and intestinal infections, particularly bacillary dysentery caused by susceptible organisms. Historically it has been used as a locally acting intestinal antiseptic rather than a modern first‑line systemic antibiotic, and its use has declined in many settings with the availability of newer agents.pubmed.ncbi.nlm.nih+2

Mechanism of action

Like other sulfonamides, sulfaguanidine inhibits folate synthesis by competitively blocking dihydropteroate synthase, the enzyme that catalyzes the incorporation of para‑aminobenzoic acid (PABA) into dihydropteroate. This inhibition impairs synthesis of dihydrofolic acid and downstream nucleotides, resulting in primarily bacteriostatic activity against a range of gram‑positive and gram‑negative intestinal bacteria.drugs.ncats+1

Pharmacokinetics relevant to lactation

Sulfaguanidine is formulated for local intestinal action and, like other “non‑absorbed” intestinal sulfonamides, exhibits low systemic bioavailability when given orally. Most of the administered dose remains within the gastrointestinal tract, where it exerts its antibacterial effect, and only a limited fraction is absorbed and distributed systemically, leading to relatively low maternal plasma concentrations.drugbank+1

Maternal toxicity and adverse effects

Because systemic absorption is limited, the risk of classic systemic sulfonamide adverse effects is reduced but not entirely absent. Potential adverse reactions include gastrointestinal upset (nausea, vomiting, diarrhea), hypersensitivity and cutaneous reactions (rash, urticaria), hematologic toxicity (e.g. agranulocytosis), and, rarely, serious idiosyncratic reactions analogous to other sulfonamides.mayoclinic+4

Excretion into breast milk

Specific data on sulfaguanidine concentrations in human milk are not available, but extrapolation from other sulfonamides indicates that, when systemically absorbed, the class is excreted into breast milk in measurable amounts. For intestinally acting agents with low absorption, such as sulfaguanidine, the expected milk levels are lower than for systemic sulfonamides, but the absence of direct measurements means some uncertainty remains.atcddd.fhi+3

Reported effects in breastfed infants

No case reports were identified that specifically attribute adverse outcomes in breastfed infants to maternal sulfaguanidine therapy. However, evidence from other sulfonamides shows that, while healthy full‑term infants beyond the neonatal period generally tolerate exposure via breast milk, theoretical risks exist in newborns, premature infants, jaundiced infants, and those with G6PD deficiency because of bilirubin displacement and potential hemolysis.who+3

Impact on lactation and breast milk

There is no evidence that sulfaguanidine directly affects milk production or the hormonal control of lactation. As with other antibiotics, its use may have indirect effects on maternal and infant gut microbiota and on the development of antibiotic resistance, but these considerations are general to antimicrobial therapy in breastfeeding rather than specific to sulfaguanidine.who+3

Clinical use in breastfeeding

In breastfeeding women with significant intestinal infections due to sulfaguanidine‑sensitive organisms, therapy may be considered when alternative agents are unsuitable, taking into account the drug’s local action and low systemic absorption. Nonetheless, standard sulfonamide precautions apply: use should be avoided, where possible, in mothers of premature, jaundiced or medically unstable infants and during the early neonatal period, whereas short‑term use may be acceptable in healthy, full‑term infants beyond the immediate newborn period when benefits clearly outweigh risks.merckmanuals+4

Infant monitoring recommendations

When sulfaguanidine is used during breastfeeding, infants—particularly those under one month of age or with risk factors—should be monitored for jaundice (including subtle scleral icterus), poor feeding, lethargy and signs of hemolysis such as pallor or dark urine. For older, healthy, full‑term infants, monitoring should focus on gastrointestinal disturbances (diarrhea, vomiting) and signs of candidiasis (oral thrush, diaper rash), as for other antibiotics taken by breastfeeding mothers.pharmaceutical-journal+5

Risk–benefit assessment

Because sulfonamides can displace bilirubin and may theoretically predispose vulnerable neonates to kernicterus, many guidelines recommend avoiding the class in late pregnancy and early neonatal breastfeeding when effective alternatives exist. For sulfaguanidine specifically, its low systemic absorption and localized intestinal action reduce, but do not eliminate, these concerns, so its use during breastfeeding is generally reserved for situations where the maternal indication is strong and alternative agents are inappropriate, while carefully considering the infant’s age and health status and the well‑established benefits of continuing breastfeeding.atcddd.fhi+4

Key counselling points

Healthcare professionals should explain that sulfaguanidine is an intestinal sulfonamide that acts mainly within the gut, with limited systemic absorption and therefore a low but not negligible potential for transfer into breast milk. Mothers should be advised that, although serious problems in breastfed infants are unlikely in most cases, particular caution is required for premature or jaundiced infants, and they should monitor their baby for jaundice, feeding difficulties or gastrointestinal symptoms and seek medical advice if these occur.drugs+5